An exploratory study of frequent pain measurement in a cancer clinical trial

Quality of Life Research

Volumn 5, Issue 5, 1996, Pages 503-507

  Ingham, J ^a   Seidman, A ^a   Yao, T J ^a   Lepore, J ^a   Portenoy, R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Clinical trials; Paclitaxel (Taxol ); Pain assessment; Quality of life

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; METASTASIS; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0029831751     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00540023     Document Type: Article

References (25)

1. Moinpour CM, Feigl R, Metch B, Hayden KA, Meyskens F Jr, Crowley J. Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst 1989; 81: 485-495.
2. Moinpour CM, Hayden KA, Thompson IM, Feigl P, Metch B. Quality of life assessment in Southwest Oncology Group trials. Oncol 1990; 4: 79-84.
3. Cella DF, Tulsky DS. Measuring quality of life today: methodological aspects. Oncol 1990; 4: 29-38.
4. Aaronson NK. Quality of life research in cancer clinical trials: a need for common rules and language. Oncol 1990; 4: 59-66.
5. Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer 1991; 67: 844-850.
6. Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson BD. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 1992; 84: 575-579.
7. Till JE, McNeil BJ, Bush RS. Measurements of multiple components of quality of life. Cancer Treat Symp 1984; 1:177.
8. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality of life assessment in cancer clinical trials In: Scheurlen H, Kay R, Baum M, eds. Recent Results in Cancer Research, Vol. 111. Berlin: Springer-Verlag, 1988: 231.
9. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
10. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
11. Hollingshead LM, Gao KL. Recombinant grariulocyte colonystimulating factor - a review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991; 42: 300-330.
12. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943-1951.
13. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol®). Sem Oncol 1993; 20: 1-15.
14. Seidman AD, Reichman BS, Crown JPA, Hakes TB, Hudis CA, Gilweski TA, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152-1159.
15. Daut RL, Cleeland CS, Flattery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17: 197-210.
16. Fishman B, Pasternak S, Wallenstein SL, Houde RW, Holland JC, Foley KM. The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain. Cancer 1987; 60: 1151-1158.
17. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. J Clin Oncol 1984; 2: 472-483.
18. Ware JE, Johnson SA, Davies-Avery A, Brook RH. Conceptualization and measurement of health for adults. Vol. 3: Mental Health. Santa Monica: Rand, 1979.
19. Veit CT, Ware JE. The structure of psychological distress and well-being in general populations. J Consult Clin Psych 1983; 51: 730-742.
20. Portenoy RK, Thaler HT, Kornblith AB, McCarthy-Lepore J, Friedlander-KIar H, Coyle N, et al. The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics, and distress. Eur J Cancer 1994; 30A: 1326-1336.
21. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer 1980; 45: 2220-2224.
22. Seidman AD, Portenoy RK, Yao T-J, Lepore J, Mont EK, Kortmansky J, et al. Quality of life in phase II trials: A study of the methodology and predictive value in advanced breast cancer patients treated with Paclitaxel plus granulocyte colony stimulating factor. J Natl Cancer Inst 87(17): 1316-1322, 1995.
23. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A, et al. Coping with the toxicities of docetaxel (Taxotere™). Ann Oncol 1993; 4: 610-611.
24. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
25. Creekmore SP, Urba WJ, Longo DL. Principles of the clinical evaluation of biological agents In: Devita VT, Hellmen S, Rosenberg SA, eds. Biologic Therapy of Cancer, First Edition. Philadelphia, PA: Lippincott Co, 1991: 67-86.